Forum Topic News
  • Conversation: Angelini Pharma acquires CNS specialist Arvelle Therapeutics

    • January 5, 2021 1:01 PM GMT
      • Post(s)

      Angelini Pharma acquires CNS specialist Arvelle Therapeutics

      Angelini Pharma has acquired Swiss biopharmaceutical company Arvelle Therapeutics for a total consideration of up to $960m.
      Arvelle specialises in developing treatment for patients with central nervous system (CNS) and mental health disorders.
      The key focus of the acquisition is Arvelle’s CNS asset cenobamate, which has been deemed a Promising Innovative Medicine by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of drug-resistant focal-onset seizures in adults.
      Following Angelini’s acquisition of Arvelle, the company will gain exclusive licensing rights to commercialise cenobamate in the European Union and other countries in the European Economic Area (including Switzerland and the UK).
      In a clinical study of cenobamate, the drug’s clinical efficacy was demonstrated after it showed a significant greater reduction in seizure frequency.
      In addition, more patients achieved a 50% or greater reduction in seizure frequency compared to the placebo group.

Add Reputation

Do you want to add reputation for this member by this post?

or cancel